Yuki Nishi, Koki Ikuno, Yuji Minamikawa, Michihiro Osumi, Shu Morioka
{"title":"Tailored transcutaneous electrical nerve stimulation improves dysesthesia in individuals with spinal cord injury: A randomized N-of-1 trial.","authors":"Yuki Nishi, Koki Ikuno, Yuji Minamikawa, Michihiro Osumi, Shu Morioka","doi":"10.1080/10790268.2025.2517929","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Current therapeutic interventions are often ineffective for dysesthesia, including tingling and allodynia, caused by spinal cord injury (SCI). Dysesthesia-matched TENS (DM-TENS) is an innovative approach for dysesthesias that customizes stimulation parameters to align with an individual's specific dysesthesia characteristics.</p><p><strong>Objective: </strong>We aimed to evaluate the efficacy of DM-TENS for dysesthesia in individuals with SCI.</p><p><strong>Design: </strong>A randomized, placebo-controlled, aggregated N-of-1 trial was conducted in six individuals with SCI.</p><p><strong>Methods: </strong>Participants received either DM-TENS as an intervention or sham TENS as a control. Each treatment was administered for 60 min/day over a 7-day period. The outcome measures included the Numeric Rating Scale (NRS) for dysesthesia and Short-Form McGill Pain Questionnaire-2 (SF-MPQ2).</p><p><strong>Results: </strong>Using a hierarchical Bayesian model, we found that dysesthesia-matched TENS provided clinically meaningful improvements in dysesthesia among individuals with SCI, with a high posterior probability (96-100%) exceeding the minimal clinically meaningful difference (NRS of 2.70) at both the individual and population levels. The mean NRS was 5.79 (95% credible interval [95% CI]: 4.58-7.01) during the placebo period, and 1.12 (95% CI: 0.59-1.66) during the DM-TENS period. In the SF-MPQ-2, the dysesthesia-matched TENS effects showed decisive evidence (BF<sub>10</sub> > 1000) for items on tender, pain caused by light touch, tingling or pins and needles, and numbness.</p><p><strong>Conclusions: </strong>This series of N-of-1 trials comparing dysesthesia-matched TENS with placebo indicated a reduction in dysesthesia in individuals with SCI. Thus, dysesthesia-matched TENS is a promising therapeutic option for managing dysesthesia in this population.<b>Trial registration:</b> UMIN Japan identifier: UMIN000050250..</p>","PeriodicalId":50044,"journal":{"name":"Journal of Spinal Cord Medicine","volume":" ","pages":"1-10"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Spinal Cord Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10790268.2025.2517929","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Current therapeutic interventions are often ineffective for dysesthesia, including tingling and allodynia, caused by spinal cord injury (SCI). Dysesthesia-matched TENS (DM-TENS) is an innovative approach for dysesthesias that customizes stimulation parameters to align with an individual's specific dysesthesia characteristics.
Objective: We aimed to evaluate the efficacy of DM-TENS for dysesthesia in individuals with SCI.
Design: A randomized, placebo-controlled, aggregated N-of-1 trial was conducted in six individuals with SCI.
Methods: Participants received either DM-TENS as an intervention or sham TENS as a control. Each treatment was administered for 60 min/day over a 7-day period. The outcome measures included the Numeric Rating Scale (NRS) for dysesthesia and Short-Form McGill Pain Questionnaire-2 (SF-MPQ2).
Results: Using a hierarchical Bayesian model, we found that dysesthesia-matched TENS provided clinically meaningful improvements in dysesthesia among individuals with SCI, with a high posterior probability (96-100%) exceeding the minimal clinically meaningful difference (NRS of 2.70) at both the individual and population levels. The mean NRS was 5.79 (95% credible interval [95% CI]: 4.58-7.01) during the placebo period, and 1.12 (95% CI: 0.59-1.66) during the DM-TENS period. In the SF-MPQ-2, the dysesthesia-matched TENS effects showed decisive evidence (BF10 > 1000) for items on tender, pain caused by light touch, tingling or pins and needles, and numbness.
Conclusions: This series of N-of-1 trials comparing dysesthesia-matched TENS with placebo indicated a reduction in dysesthesia in individuals with SCI. Thus, dysesthesia-matched TENS is a promising therapeutic option for managing dysesthesia in this population.Trial registration: UMIN Japan identifier: UMIN000050250..
期刊介绍:
For more than three decades, The Journal of Spinal Cord Medicine has reflected the evolution of the field of spinal cord medicine. From its inception as a newsletter for physicians striving to provide the best of care, JSCM has matured into an international journal that serves professionals from all disciplines—medicine, nursing, therapy, engineering, psychology and social work.